Effects of Flavonoid Compounds on β-amyloid-peptide-induced Neuronal Death in Cultured Mouse Cortical Neurons

Seong-Min Choi, Byeong C. Kim*, Yeun-Hee Cho, Kang-Ho Choi, Jane Chang, Man-Seok Park, Myeong-Kyu Kim, Ki-Hyun Cho and Jong-Keun Kim

Departments of Neurology and Pharmacology, Chonnam National University Medical School, Gwangju, Korea

Excessive accumulation of β-amyloid peptide (Aβ) is one of the major mechanisms responsible for neuronal death in Alzheimer’s disease. Flavonoids, primarily antioxidants, are a group of polyphenolic compounds synthesized in plant cells. The present study aimed to identify flavonoid compounds that could inhibit Aβ-induced neuronal death by examining the effects of various flavonoids on the neurotoxicity of Aβ fragment 25-35 (Aβ25-35) in mouse cortical cultures. Aβ25-35 induced concentration- and exposure-time-dependent neuronal death. Neuronal death induced by 20 μM Aβ25-35 was significantly inhibited by treatment with either Trolox or ascorbic acid. Among 10 flavonoid compounds tested [apigenin, baicalein, catechin, epicatechin, epigallocatechin gallate (EGCG), kaempferol, luteolin, myricetin, quercetin, and rutin], all except apigenin showed strong 1,1-diphenyl-2-pycrylhydrazyl (DPPH) scavenging activity under cell-free conditions. The flavonoid compounds except apigenin at a concentration of 30 μM also significantly inhibited neuronal death induced by 20 μM Aβ25-35 at the end of 24 hours of exposure. Epicatechin, EGCG, luteolin, and myricetin showed more potent and persistent neuroprotective action than did the other compounds. These results demonstrated that oxidative stress was involved in Aβ-induced neuronal death, and antioxidative flavonoid compounds, especially epicatechin, EGCG, luteolin, and myricetin, could inhibit neuronal death. These findings suggest that these four compounds may be developed as neuroprotective agents against Alzheimer’s disease.

Key Words: β-Amyloid peptide; Alzheimer’s disease; Flavonoids

INTRODUCTION

Flavonoids make up the most common group of polyphenolic compounds in the human diet that are synthesized in plant cells. Flavonoids have a 15-carbon skeleton consisting of two fused six-membered rings (an aromatic ring and a heterocyclic ring) connected through a carbon-carbon bridge to an aromatic ring. The flavonoids can be divided into six different major classes (flavonols, flavanones, flavones, isoflavones, catechins, and anthocyanidins) on the basis of differences in the structure of their molecular backbone. The major sources of flavonoids include fruits, vegetables, tea, wine, and cocoa. The flavon quercetin and the flavone apigenin are found in onions, apples, broccoli, and berries. The flavanone naringenin is found in citrus foods. Catechins are abundant in green tea. Cyanidin and other anthocyanidins are largely responsible for the deep colors of berries, grapes, and red wine. Genistein is an isoflavone found predominantly in legumes. The flavonoid consumed most, in general, is quercetin, and the richest sources of flavonoids consumed in general are tea, onions, and apples. Flavonoids contain a number of phenolic hydroxyl groups attached to ring structures, which may act as antioxidants, as radical-scavenging agents, or as agents of anti-inflammation. Recently, significant evidence has emerged to indicate that the consumption of flavonoid-rich foods is associated with lower rates of dementia and beneficial effects on memory and learning. Alzheimer’s disease (AD) is the major subtype of de-
mentia in all age groups. AD is a progressive neurodegenerative disorder associated with a disruption of neuronal function and a clinically gradual deterioration in remembering recent events, thinking abilities, and behavior. AD is pathologically characterized by the presence of neuritic plaques, neurofibrillary tangles, and the loss of cortical neurons and synapses, which is a hallmark feature of the AD brain. The β-amyloid peptide (Aβ) is the major component of extracellular neuritic plaques. Aβ is 39 to 43 amino acid fragments in length and is generated by proteolytic cleavage of the larger amyloid precursor protein (APP), a ubiquitously expressed transmembrane glycoprotein. An excessive accumulation of Aβ is one of the significant factors responsible for neuronal death in AD.

Among the Aβ fragments (Aβ25-35, Aβ1-40, and Aβ1-42) that have toxic effects on neurons in vitro, Aβ25-35 is one of the short peptide sequences that retains biological activity comparable with that of full-length Aβ. Although the precise mechanisms mediating Aβ-induced neuronal death have yet to be fully established, it is well known that Aβ-induced neuronal death is associated with the generation of reactive oxygen species in the brain. Aβ-induced neuronal death is associated with the generation of a cascade of intracellular events that culminates in neuronal death via calcium-permeable cation channels as well as free-radical-like action.

To determine the antioxidant potencies of 10 types of flavonoids in vitro, and to identify some flavonoid compounds that could inhibit Aβ-induced neuronal death, we investigated the effects of various flavonoids on neuronal death induced by Aβ25-35 in mouse cortical cultures.

**MATERIALS AND METHODS**

1. **Materials**

   Eagle’s minimal essential medium (MEM) and Hanks’ balanced solution were purchased from Gibco (Gaithersburg, MD, USA). Fetal bovine serum (FBS) and horse serum were obtained from Hyclone (Logan, UT, USA). HEPES (acid), glucose, NaHCO3, NaCl, KCl, MgCl2, CaCl2, NaOH, phenol red, trypsin, cytosine arabinoside, epidermal growth factor, sucrose, ascorbic acid, cycloheximide, apigenin, baicalein, catechin, epicatechin, epigallocatechin gallate (EGCG), kaempferol, luteolin, myricetin, quercetin, rutin, nifedipine, flunarizine, diltiazem, NMDA, MK-801, Trolox, and Aβ25-35 were all purchased from Sigma-Aldrich (St. Louis, MO, USA).

2. **Methods**

   1) **Cortical cell cultures:** Mixed cortical cell cultures, including both neurons and glia, were prepared with minor modification of the methods described by Choi et al. Pregnant mice (Institute of Cancer Research, London, UK) aged 1 to 2 days. Dissection and dissociation were as described above for mixed cortical cell cultures, and cells were plated in 24-well multi-well plates at a density of 0.5 hemispheres/plate (approximately 2.5×10^5 cells per well). The plates were plated in an incubator (Forma Company, USA) at 37°C, 5% CO2, with humidified air. Cytosine arabinoside was added to produce a final concentration of 10 μM at 5 days in vitro and the plates were maintained for 2 days to halt non-neuronal cell division. The culture medium was changed twice a week after 7 days in vitro. Cultures were used at 13 or 14 days in vitro for the experiments.

   Cortical glial cultures were prepared from postnatal mice (Institute of Cancer Research, London, UK) aged 1 to 2 days. Dissection and dissociation were as described above for mixed cortical cell cultures, and cells were plated in 24-well multi-well plates at a density of 0.5 hemispheres/plate. The plating medium was supplemented with Eagle’s MEM containing 2 mM glutamine, 10% FBS, 10% horse serum, and 10 ng/mL of epidermal growth factor. The plates were maintained in the same incubator. The culture medium was changed once a week after 14 days in vitro. Glial cultures were used for the plating of mixed cortical cell cultures between 18 and 24 days in vitro.

   The procedures involving experimental animals complied with the regulations for the care and use of laboratory animals of the animal ethical committee of Chonnam National University.

   2) **Neurotoxicity and flavonoid experiments:** Cultured cells in 24-well multi-well plates were used for experimentation at 13 to 14 days in vitro. After washing with MEM, cultures were exposed to Aβ25-35, Trolox, ascorbic acid, and various flavonoids for 24 or 48 hours.

   Each row of the 24-well plates had 4 wells that were part of the same experiment. The four wells in the first row were treated with sham wash, NMDA (500 μM) treatment was given for full killing of neurons in the second row, and the third to the sixth rows were treated with drugs. The amount of each drug was 4 to 8 μL in each well with culture media. To evaluate the protective effects of these drugs on Aβ25-35-induced injury, the authors treated the cultures with two drugs simultaneously.

   3) **Analysis of neuronal survival:** Cell viability of the cultures was assessed according to morphological characteristics under phase-contrast microscopy. The extent of neuronal injury was evaluated at the termination of Aβ ex-
posure for 24 hours and was based on the amount of lactate dehydrogenase (LDH) released into the medium at the end of the exposure period. Neuronal injury was quantified by measurement of LDH in the culture medium. LDH activity in the medium was measured as described by Koh and Choi. For the measurement of LDH, a phase-contrast microscope after exposure to 20 μM Aβ25-35 for 24 hours. On the basis of LDH measurements in the culture medium, approximately 16±2.6% or 52±3.1% of cells were damaged by 20 μM Aβ25-35 for 24 or 48 hours. On the basis of LDH measurements in the culture media, at a concentration of 20 μM Aβ25-35, approximately 20% or 50% of cells were damaged after exposure for 24 or 48 hours, respectively (Fig. 1C). Even when the concentration of Aβ25-35 was increased to 40 and 80 μM, the LDH measurement was similar with that induced by 20 μM of Aβ25-35 (Fig. 1C). Neurotoxicity was not induced by the reverse sequence of the Aβ25-35 peptide.

5) Data analysis: Experiments were set up with 8 to 12 replicate samples. Results are expressed as means±SEM values, and the agents’ effects were statistically evaluated with analysis of variance (one-way ANOVA) followed by the Student-Newman-Keuls post hoc test. Statistical significance was considered at value of p < 0.05.

RESULTS

1. Aβ25-35-induced neurotoxicity of cultured neurons

To evaluate the neurotoxicity of Aβ25-35, primary cultures of mouse cortical cells containing neuronal and non-neuronal cells maintained for 13 to 14 days in vitro were exposed to Aβ25-35 at each concentration (5, 10, 20, 40, and 80 μM) for 24 or 48 hours. Aβ25-35 within a concentration range of 5 to 20 μM produced concentration-dependent neurotoxicity in cultured cortical neurons. Therefore, we used 20 μM Aβ25-35 to induce neuronal cell damage in the following experiments.

Neuronal cell damage (Fig. 1A, B) was observed under a phase-contrast microscope after exposure to 20 μM Aβ25-35 for 24 hours. On the basis of LDH measurements in the culture media, at a concentration of 20 μM Aβ25-35, approximately 20% or 50% of cells were damaged after exposure for 24 or 48 hours, respectively (Fig. 1C). Even when the concentration of Aβ25-35 was increased to 40 and 80 μM, the LDH measurement was similar with that induced by 20 μM of Aβ25-35 (Fig. 1C). Neurotoxicity was not induced by the reverse sequence of the Aβ25-35 peptide.

2. Effects of antioxidants on Aβ25-35-induced neuronal death

Free radical injury is one of the most common and important ways of inducing neuronal death. Aβ-induced neuronal death is also related to oxidative cell damage. To evaluate whether antioxidants such as Trolox and ascorbic acid could prevent Aβ25-35-induced neuronal death in cultured neurons, the amount of LDH release in the culture media was measured after exposure of the cultured neurons to 20 μM Aβ25-35 for 24 or 48 hours. On the basis of LDH measurements in the culture media, approximately 16±2.6% or 52±3.1% of cells were damaged by 20 μM Aβ25-35 treatment for 24 hours (n=12) or 48 hours (n=12), respectively (Fig. 2A). Pretreatment with 100 μM Trolox reduced Aβ25-35-induced neuronal cell damage (Fig. 2B). Pretreatment with 100 μM Trolox reduced Aβ25-35-induced neuronal cell damage (Fig. 2B).
duced LDH release to 4±3% (n=8) for 24 hours and 8±2.7% (n=8) for 48 hours, and 100 μM ascorbic acid reduced LDL release to 0±1.4% (n=8) for 24 hours and 5±2.5% (n=8) for 48 hours (Fig. 2).

3. Antioxidant activities of flavonoid compounds

According to the above data, the antioxidants Trolox and ascorbic acid strongly inhibited Aβ25-35-induced neuronal death. To test the antioxidant effects of flavonoid compounds in neuronal death, we used apigenin, baicalein, catechin, epicatechin, EGCG, kaempferol, luteolin, myricetin, quercetin, and luteolin as the flavonoid compounds. Scavenging of free radical DPPH is the basis of a common antioxidant assay. We therefore used the stable free radical DPPH to estimate the antioxidant activity of the flavonoid compounds. This method examines the use of the parameter IC50 (the concentration of substrate that causes 50% loss of the DPPH activity). All of the flavonoid compounds except for apigenin had strong antioxidant effects. Compared with the antioxidant effects of Trolox, kaempferol had similar effects, whereas the others had stronger antioxidant effects (Table 1).

4. Effects of flavonoids on Aβ25-35-induced neuronal death

Cultured neurons were treated with 20 μM Aβ25-35 for 24 or 48 hours and 30 μM of each flavonoid, and the amount of LDH release in the culture media was measured. Except for apigenin, all flavonoids inhibited Aβ25-35-induced neuronal death for 24 hours, but these protective effects were not maintained for 48 hours for baicalein, catechin, kaempferol, quercetin, and rutin (Table 2).

To determine whether the 3 flavonoids EGCG, luteolin, and myricetin could prevent Aβ25-35-induced neuronal death in cultured neurons, LDH release was measured after exposure of the neurons to 20 μM Aβ25-35 for 24 and 48 hours. To determine the flavonoid concentration for neuroprotective effects, we selected 3 flavonoids (EGCG, luteolin, myricetin) that inhibited Aβ25-35-induced neuronal death for 24 and 48 hours. Treatment with EGCG (3, 10, or 30 μM) significantly attenuated LDH release by Aβ25-35-induced neuronal death in a dose-dependent manner compared with the control (Fig. 3A). Compared with LDH release after treatment with 20 μM Aβ25-35 (21±2.3% at 24 hours, n=12, and 46±3.2% at 48 hours, n=12), pretreatment with 3, 10, or 30 μM EGCG reduced LDL release to 9±1.6%, 4±1.6%, and 1±0.4% at 24 hours (n=12) and to 20±2.5%, 8±1.6%, and 4±3.0% at 48 hours (n=12), respectively (Fig. 3A). Compared with LDH release after

Table 1. Antioxidant ability of various flavonoids against the free radical DPPH

| Flavonoids | Scavenging DPPH | % inhibition at 30 μM* | IC50 (μM)b |
|------------|-----------------|-----------------------|------------|
| Apigenin   |                 | 0.2±0.5               | –          |
| Baicalein  |                 | 65±1.4                | 21.2       |
| Catechin   |                 | 79±0.9                | 15         |
| EGCG       |                 | 82±0.2                | 6.7        |
| Epicatechin|                 | 75±1.1                | 19         |
| Kaempferol |                 | 42±1.0                | 34.4       |
| Luteolin   |                 | 76±0.5                | 14.8       |
| Myricetin  |                 | 78±0.4                | 10.5       |
| Quercetin  |                 | 79±1.4                | 14.5       |
| Rutin      |                 | 67±3.9                | 17         |
| Trolox     |                 | 52±1.6                | 34.1       |

DPPH: 1,1-diphenyl-2-picrylhydrazyl, EGCG: epigallocatechin gallate. *Represents the inhibition (%) of DPPH activity at the 30 μM concentration of each flavonoid. bRepresents the concentration of substrate that causes 50% loss of the DPPH activity.

Table 2. Effects of some flavonoids on 20 μM Aβ25-35-induced neuronal death

| Flavonoids (30 μM) | LDH release after exposure of 20 μM Aβ25-35 |
|--------------------|---------------------------------------------|
|                     | For 24 hours                                | For 48 hours                                |
| Control             | 21±1.1                                      | 46±1.9                                      |
| Apigenin            | 23±2.0                                      | 44±2.8                                      |
| Baicalein           | 12±1.4a                                     | 49±2.4                                      |
| Catechin            | 12±1.7a                                     | 37±3.6                                      |
| Epicatechin         | 3±1.4a                                      | 13±2.4†                                     |
| EGCG                | 1±0.4e                                      | 4±3.0†                                      |
| Kaempferol          | 7±1.8a                                      | 46±2.3                                      |
| Luteolin            | 1±1.4a                                      | 19±5.4†                                     |
| Myricetin           | 1±1.6e                                      | 15±1.6†                                     |
| Quercetin           | 10±2.0a                                     | 51±3.9                                      |
| Rutin               | 7±1.1e†                                     | 51±3.4                                      |

Aβ25-35: β-amyloid peptide fragment 25-35, LDH: lactate dehydrogenase, EGCG: epigallocatechin gallate. Numerals are the calculated percentage (mean±SE) of LDH release from 4×52 wells compared with complete neuronal death. * and † represent significant differences for 24 hours and 48 hours compared with the control group, respectively (p<0.05).
treatment with 20 µM Aβ25-35 (20±2.7% at 24 hours, n=12, and 42±1.8% at 48 hours, n=12), pretreatment with 3, 10, or 30 µM luteolin reduced LDH release to 2±1.6%, 0±2.2%, and 1±1.4% at 24 hours (n=12) and to 36±3.4%, 38±2.6%, and 19±4.3% at 48 hours (n=12), respectively (Fig. 3B). At 24 hours, all concentrations of luteolin from 3 µM to 30 µM almost completely inhibited Aβ25-35-induced neuronal death, but at 48 hours, only 30 µM luteolin significantly inhibited Aβ25-35-induced neuronal death (Fig. 3B). In the experiment with myricetin, when cortical neurons were exposed to 20 µM Aβ25-35 for 24 or 48 hours, the amounts of LDH release in the culture media were 23±1.7% (n=12) and 50±1.9% (n=12), respectively. Pretreatment with myricetin (3, 10, and 30 µM) reduced Aβ25-35-induced LDH release to 3±1.8%, 1±2.1%, and 1±1.6% at 24 hours (n=12) and to 34±4.9%, 31±2.8%, and 15±1.6% at 48 hours (n=12), respectively (Fig. 3C).

**DISCUSSION**

The results of the present study showed that Aβ25-35 treatment induced neuronal death that was dependent on dosage and exposure time, whereas the inverted amino acid sequence Aβ35-25 failed to induce neuronal death. These results suggest that Aβ25-35-induced neuronal death is specific. In addition, although increasing the concentration of Aβ25-35 to at least 20 µM made a difference between a 24-hour time frame and a 48-hour time frame, there was no significant difference in the maximum effect within the same time frame. Subsequently, these results imply that Aβ25-35 acted selectively on only a fraction of the cultured neurons, which suggests that further investigation is needed.

In this study, treatment with the antioxidants Trolox and ascorbic acid noticeably blocked Aβ-induced neuronal death. In addition, among the 10 different flavonoid compounds tested in this study, the free radical scavenging inactive compound apigenin failed to block Aβ-induced neuronal death in DPPH scavenging-activity tests, whereas all other compounds significantly blocked Aβ-induced neuronal death after a 24-hour time frame. These results indicate that Aβ-induced neuronal death is associated with oxidative damage due to free radical formation. In fact, many studies suggest that oxidative damage is associated with Aβ-induced neuronal death.

A search on free radical DPPH scavenging activity yielded a sequence of highest to lowest activity as follows: EGCG > myricetin > quercetin = luteolin = catechin ≥ rutin ≥ epicatechin ≥ baicalein ≥ kaempferol = Trolox (Table 1). Such results indicate that the majority of the flavonoid compounds used in this study had a higher level of antioxidant activity than that of Trolox. Additionally, the inhibitory action of flavonoid compounds at a concentration of 30 µM on Aβ-induced neuronal death was (highest to lowest) as follows: EGCG = luteolin = myricetin = epicatechin > kaempferol = rutin ≥ quercetin ≥ baicalein = catechin (Table 2). Although there are some discrepancies between the rankings for antioxidant activity and those for the in-
hibitory activity of Aβ-induced neuronal death for some of these flavonoids, the finding that EGCG, the compound with the most antioxidant activity, also had the highest inhibitory activity on Aβ-induced neuronal death implies a possible correlation. In a previous study, free radical DPPH scavenging activity was related with total phenolic content, which was related to cell viability in Aβ25-35-induced hippocampal neuronal death. Rice-Evans et al. reported that upon measuring an alternate antioxidant activity marker such as Trolox-equivalent antioxidant activity (TEAC) in various flavonoid compounds, apigenin had greater antioxidant activity than kaempferol, and all other flavonoid compounds still had higher antioxidant activity than Trolox. The present study found that apigenin had negligible free radical DPPH scavenging activity as well as no influence on Aβ-induced neuronal death, which is not compatible with the findings of previous studies. This result may be due to the use of free radical DPPH scavenging activity, which better reflects antioxidant activity on Aβ compared with TEAC. However, an explanation for why apigenin exhibited differing results for free radical DPPH scavenging activity versus TEAC remains to be investigated.

Among the flavonoid compounds used in this study, epicatechin, EGCG, luteolin, and myricetin showed the strongest inhibitory effects, which were maintained after a 48-hour time frame. The dose response tests of EGCG, luteolin, and myricetin showed that a low concentration of 3 to 10 μM significantly blocked Aβ-induced neuronal death. In particular, luteolin and myricetin had stronger inhibitory effects than did EGCG. On the basis of these results and considering that EGCG exhibited stronger inhibitory effects than luteolin or myricetin for free radical DPPH scavenging activity, the inhibitory effects of these compounds on Aβ-induced neuronal death may not always be proportional to antioxidant activity. Nevertheless, the inhibitory effect of EGCG on Aβ-induced neuronal death was substantially stronger after a 48-hour time frame. The difference between the levels of inhibition at 24 hours compared with 48 hours may be dependent on the chemical properties of the compounds, but this will require further inquiry.

Ginkgo biloba extract EGb 761 has been gaining attention for its effects in memory enhancement in the treatment of Alzheimer’s disease. The structure of EGb 761 as a polymer made up of basic flavonoids and reports that this drug blocks Aβ-induced neuronal death in cultured neurons suggest the potential of the various flavonoid compounds analyzed in this study to be developed as neuroprotectant agents. Currently, active studies are being done to develop compounds, including both flavonoids and antioxidants, for use as possible drugs to treat neurodegenerative diseases.

In conclusion, this study was undertaken to analyze the effects of 10 different flavonoid compounds (apigenin, baicalein, catechin, epicatechin, EGCG, kaempferol, luteolin, myricetin, quercetin, and rutin) to search for a flavonoid compound that can be developed as a new drug to treat Aβ-induced neuronal death. Aβ25-35-induced neuronal death was dependent on dosage and exposure time. The results of this study indicated the presence of oxidative damage during Aβ-induced neuronal death and that flavonoid compounds with free radical scavenging activity can block Aβ-induced neuronal death. Finally, the results suggest that compounds that have strong inhibitory effects against Aβ25-35-induced neuronal death, such as epicatechin, EGCG, luteolin, and myricetin, have the potential to be developed into new drugs for the treatment of Alzheimer’s disease.

ACKNOWLEDGEMENTS

This study was supported by a grant of the Korean Health Technology R&D Project A121751 (to KH Choi) funded by the Ministry of Health & Welfare, Republic of Korea, and a grant from the Brain Research Program through the National Research Foundation of Korea funded by the Ministry of Science, ICT & Future Planning NRF-2013M3C7A1072997 (to BC Kim).

CONFLICT OF INTEREST STATEMENT

None declared.

REFERENCES

1. Robards K, Antolovich M. Analytical chemistry of fruit bioflavonoids. A review. Analyst 1997;122:11R-34.
2. Lu MF, Xiao ZT, Zhang HY. Where do health benefits of flavonoids come from? Insights from flavonoid targets and their evolutionary history. Biochem Biophys Res Commun 2013;434:701-4.
3. Beecher GR. Overview of dietary flavonoids: nomenclature, occurrence and intake. J Nutr 2003;133:3248S-54.
4. Harnly JM, Doherty RF, Beecher GR, Holden JM, Haytowitz DB, Bhagwat S, et al. Flavonoid content of U.S. fruits, vegetables, and nuts. J Agric Food Chem 2006;54:9966-77.
5. Hertog MG, Feskens EJ, Doll H, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 1993;342:1007-11.
6. Rice-Evans CA, Miller NJ, Paganga G. Structure-antioxidant activity relationships of flavonoids and phenolic acids. Free Radic Biol Med 1996;20:933-56.
7. Pietta PG. Flavonoids as antioxidants. J Nat Prod 2000;63:1035-42.
8. Zeng LH, Zhang HD, Xu CJ, Bian YJ, Xu XJ, Xie QM, et al. Neuroprotective effects of flavonoids extracted from licorice on kainate-induced seizure in mice through their antioxidant properties. J Zhejiang Univ Sci B 2013;14:1004-12.
9. Dugas AJ Jr, Castañeda-Acosta J, Bonin GC, Price KL, Fischer NH, Winston GW. Evaluation of the total peroxyl radical-scavenging capacity of flavonoids: structure-activity relationships. J Nat Prod 2000;63:327-31.
10. Cho JG, Song NY, Nam TG, Shrestha S, Park HJ, Lyu HN, et al. Flavonoids from the grains of C1/R-S transgenic rice, the transgenic Oryza sativa ssp. japonica, and their radical scavenging
activities. J Agric Food Chem 2013;61:10354-9.
11. Nijveldt RJ, van Noord E, van Hoorn DE, Boelens PG, van Norren K, van Leeuwen PA. Flavonoids: a review of probable mechanisms of action and potential applications. Am J Clin Nutr 2001;74: 418-25.
12. Thilakarathna SH, Rupasinghe HP. Flavonoid bioavailability and attempts for bioavailability enhancement. Nutrients 2013;5: 3367-87.
13. Beking K, Vieira A. Flavonoid intake and disability-adjusted life years due to Alzheimer's and related dementias: a population-based study involving twenty-three developed countries. Public Health Nutr 2010;13:1403-9.
14. Letenneur L, Proust-Lima C, Le Gouge A, Dartigues JF, Letenneur L, Proust-Lima C, Le Gouge A, Dartigues JF, et al. Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurology 2000;54 (11 Suppl 5):S10-5.
15. Terry RD, Masliah E, Salmon DP, Butters N, De Teresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991;30:572-80.
16. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 1985;82:4245-9.
17. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 1985;82:4245-9.
18. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987;325: 733-6.
19. Small DH, McLean CA. Alzheimer's disease and the amyloid beta protein: What is the role of amyloid? J Neurochem 1999;73:443-9.
20. Small DH, Mok SS, Bornstein JC. Alzheimer's disease and Abeta toxicity: from top to bottom. Nat Rev Neurosci 2001;2:595-8.
21. Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci 1993;13:1676-87.
22. Jordán J, Galindo MF, Miller RJ. Role of calpain- and interleukin-1 beta converting enzyme-like proteases in the beta-amyloid-induced death of rat hippocampal neurons in culture. J Neurochem 1997;68:572-80.
23. Bastianetto S, Ramassamy C, Dore S, Christen Y, Poirier J, Quirion R. The Ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by beta-amyloid. Eur J Neurosci 2000;12:1882-90.
24. Bisaglia M, Venezia V, Piccioli P, Stanzione S, Porcile C, Russo C, et al. Acetaminophen protects hippocampal neurons and PC12 cultures from amyloid beta-peptides induced oxidative stress and reduces NF-kappaB activation. Neurochem Int 2002;41:43-54.
25. Pike CJ, Walencewicz-Wasserman AJ, Kosmoski J, Cribbs DH, Glabe CG, Cotman CW. Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity. J Neurochem 1995;64:253-65.
26. Smid SD, Maag JL, Munschlag IF. Dietary polyphenol-derived protection against neurotoxic β-amyloid protein: from molecular to clinical. Food Funct 2012;3:1242-50.
27. Hensley K, Carney JM, Mattson MP, Aksenova M, Harris M, Wu JF, et al. A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc Natl Acad Sci U S A 1994;91:3270-4.
28. Mattsson MF, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE. Beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 1992;12:376-89.
29. Choi DW, Maulucci-Gedde M, Kriegstein AR. Glutamate neurotoxicity in cortical cell culture. J Neurosci 1987;7:357-68.
30. Pike CJ, Walencewicz AJ, Glabe CG, Cotman CW. In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res 1991;563:311-4.
31. Koh J, Choi DW. Quantitative determination of glutamate mediated cortical neuronal injury in cell culture by lactate dehydrogenase efflux assay. J Neurosci Methods 1987;20:83-90.
32. Goodman Y, Steiner MR, Steiner SM, Mattson MP. Nondihydroguaiaretic acid protects hippocampal neurons against amyloid beta-peptide toxicity, and attenuates free radical and calcium accumulation. Brain Res 1994;654:171-6.
33. Bruce AJ, Malfroy B, Baudry M. beta-Amyloid toxicity in organotypic hippocampal cultures: protection by EUK-8, a synthetic catalytic free radical scavenger. Proc Natl Acad Sci U S A 1996;93:2312-6.
34. Okada Y, Okada M. Protective effects of plant seed extracts against amyloid β-induced neurotoxicity in cultured hippocampal neurons. J Pharm Bioallied Sci 2013;5:1409-15.
35. Liu R, Zhang T, Yang H, Lan X, Ying J, Du G. The flavonoid apigenin protects brain neurovascular coupling against amyloid-β1-42-induced toxicity in mice. J Alzheimers Dis 2011;24:85-100.
36. Oken BS, Storzbach DM, Kaye JA. The efficacy of Ginkgo biloba to cognitive function in Alzheimer disease. Arch Neurol 1998;55: 1409-15.
37. Drieu K. Preparation and definition of Ginkgo biloba extract. Presse Med 1986;15:1455-7.
38. Moosmann B, Behl C. Antioxidants as treatment for neurodegenerative disorders. Expert Opin Investig Drugs 2002;11:1407-35.
39. Youdim KA, Spencer JP, Schroeter H, Rice-Evans C. Dietary flavonoids as potential neuroprotectants. Biol Chem 2002;383: 503-19.
40. Gao J, Inagaki Y, Li X, Kokudo N, Tang W. Research progress on natural products from traditional Chinese medicine in treatment of Alzheimer's disease. Drug Discov Ther 2013;7:46-57.
41. Jones QR, Warford J, Rupasinghe HP, Robertson GS. Target-based selection of flavonoids for neurodegenerative disorders. Trends Pharmacol Sci 2012;33:602-10.